Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVLK.L Share News (VLK)

  • There is currently no data for VLK

Small Cap round-up: Vislink, Source BioScience, Alliance Pharma..........

Wed, 24th Mar 2010 18:43
New chief executive Duncan Lewis has restructured Vislink's operations so they are based on customer sectors rather than technologies. The core news and entertainment division reported much lower revenues as its major US contract came to an end. The law enforcement division is benefiting from increased spending on surveillance equipment and the marine division is gaining work onshore. Revenues fell from £101m to £94.7m in 2009. The underlying operating profit declined by two-fifths to £5.22m and pre-tax profit slumped from £8.77m to £4.75m. The dividend is unchanged at 1.25p a share. Net cash was £611,000 at the end of 2009. Capitalised development spending increased from £2.95m to £3.2m. The order book was worth £20.3m at the end of 2009. Cost savings will help profits to recover this year. Evolution forecasts that profits will improve to £8.6m in 2010. Asia and the Middle East provide the most opportunities. Vislink is ready to make acquisitions and they are likely to be in Asia so that the company has a base in the region. Healthcare and life sciences services provider Source BioScience moved into profit in 2009. There was a swing from a loss of £300,000 to a profit of £200,000 on revenues that were 11% higher at £12.7m. All three divisions made a positive contribution in the year. Source is investing in DNA sequencing equipment and expects this to be a growth area. The outsourced pharma services operation made its first profit. Alliance Pharma reported a 44% increase in revenues to £31.2m in 2009 thanks to a combination of organic and acquisitive growth. Pre-exceptional profits jumped from £2.4m to £8.6m, although that doesn't include a £2.8m write-off mainly relating to the capitalised development costs of a drug. Alliance specialises in mature drugs and treatments which have a solid revenue base. Some of its drugs are more than 50 years old but they still have significant revenues. The recent purchase of Cambridge Laboratories for up to £16.4m has added cancer drugs to the portfolio. A much-improved second half performance helped eg solutions to return to profit in the year to January 2010. The operations management software supplier reported a 13% increase in revenues to £4.15m. A loss of £753,000 was turned into a profit of £99,000 in 2009. Higher gross margins and cost cutting were behind the improvement. More software licences were sold in the most recent period. Weak construction demand has hit trading at quantity surveyor Baqus and although work is being won it is at lower margins than in the past. The order book is flat at £8m. Management had already warned that the interim figures would be disappointing. Revenues fell from £3.98m to £3.85m in the six months to December 2009. A profit of £365,000 has turned into a loss of £470,000, including an exceptional charge for redundancies and office closures.

Related News

Alliance Pharma loss narrows in 2024 due to reduced impairment charges
8 Apr 2025

Alliance Pharma loss narrows in 2024 due to reduced impairment charges

(Alliance News) - Alliance Pharma PLC on Tuesday reported a narrowed loss for 2024 despite a decline in revenue, due to a reduction in impairment char...

Alliance Pharma confident despite softer sales
8 Apr 2025

Alliance Pharma confident despite softer sales

(Sharecast News) - Alliance Pharma posted weaker full-year revenues on Tuesday, but insisted it remained well-positioned for medium-term growth.

Alliance Pharma board backs final GBP362 million takeover bid
10 Mar 2025

Alliance Pharma board backs final GBP362 million takeover bid

(Alliance News) - Alliance Pharma PLC on Monday said it has agreed to a final increased cash offer of 64.75 pence per share from Dbay Advisors Ltd and...

VLK.L News

Vislink posts increase in 2012 profit and revenue
25 Mar 2013

Vislink posts increase in 2012 profit and revenue

Vislink returned to profit in 2012 as the technology group achieved strong performance in the broadcast and surveillance sectors. Adjusted operating...

Two Fenner directors snap up shares
26 Apr 2012

Two Fenner directors snap up shares

John Sheldrick, a Non-Executive Director of FTSE 250 polymer technology firm Fenner, bought himself 10,000 shares just one day after the company unvei...

Small caps round-up: Clean Air Power, ZOO Digital, Hasgrove...
26 Apr 2012

Small caps round-up: Clean Air Power, ZOO Digital, Hasgrove...

Clean Air Power, a combustion technology developer, has announced that supermarket chain Sainsbury has increased its order for an additional 10 units ...

Small caps round-up: Plastics Capital, Vislink, Westminster Group ...
25 Apr 2012

Small caps round-up: Plastics Capital, Vislink, Westminster Group ...

Plastics Capital, a niche platics products group, has said it expects its result for the full year to 31 March 2012 will be in line with market expect...

Ophir Energy director makes massive sale
2 Apr 2012

Ophir Energy director makes massive sale

Rajan Tandon, a Non-Executive Director of FTSE 250 African energy firm Ophir, has ditched 10m shares in the firm, cashing in on the recent surge in it...

Maintel sales director reduces sizeable stake in firm
28 Mar 2012

Maintel sales director reduces sizeable stake in firm

Angus McCaffery, Sales and Marketing Director of Maintel, a telecoms and data services company, sold off 115,000 ordinary shares for 380p each. The ...

Lancashire's president sells £1.39m worth of shares
9 Nov 2011

Lancashire's president sells £1.39m worth of shares

The president of Lancashire Holdings, the FTSE 250 insurance broker, has sold 330,000 shares in the firm less than one week after the firm paid a spec...

TechMARK movers: Microgen pleases market
24 Feb 2011

TechMARK movers: Microgen pleases market

Full year figures from software provider Microgen were well received making it one of the few risers on TechMARK today. Revenue from continuing ope...